Patents
Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128)
11/2002
11/19/2002US6482418 Substitutes for silicone oils
11/19/2002US6482417 Stable pharmaceutical formulation comprising torsemide modification II
11/19/2002US6482413 Vitamin B12 —biodegradable micro particulate conjugate carrier systems for peroral delivery of drugs, therapeutic peptides/proteins and vaccines
11/19/2002US6482410 Mediation of neuronal attachment and enhancement of the outgrowth of neutites
11/19/2002US6482401 Chondroitin and glucosamine
11/19/2002US6481435 Closure-cap and container as a two-chamber cartridge for nebulizers for producing aerosols and active substance formulations, suitable for storage
11/19/2002CA2312667C Novel cytokine
11/19/2002CA2273026C Non-irritating cosmetic and pharmaceutical compositions
11/19/2002CA2154432C Cosmetic and/or dermatologic composition containing thermal or mineral water and an anti-acne and anti-aging active ingredient
11/19/2002CA2050970C Pharmaceutical compositions containing furan derivatives
11/15/2002WO2001087347A1 Heterobifunctional cross-linking agent conjugate substituted by an immunomodulator and cell recognition unit
11/15/2002CA2409255A1 Heterobifunctional cross-linking agent conjugate substituted by an immunomodulator and cell recognition unit
11/15/2002CA2386430A1 Simethicone as weight gain enhancer
11/15/2002CA2385782A1 Pharmaceutical composition for both intraoral and oral administration
11/14/2002WO2002090417A1 Biodegradable copolymers linked to segment with a plurality of functional groups
11/14/2002WO2002090390A1 Hyaluronic acid containing bioconjugates : targeted delivery of anti-cancer drugs to cancer cells
11/14/2002WO2002090361A1 Metal substituted non centrosimmetrical phthalocyanine analogues, their preparation and use in photodynamic therapy and in vivo diagnostic
11/14/2002WO2002090304A1 Stable solution of reduced coenzyme q
11/14/2002WO2002089917A2 Dermatological formulations
11/14/2002WO2002089868A1 Fibrin material and method for producing and using the same
11/14/2002WO2002089858A1 Azo compounds for type i phototherapy
11/14/2002WO2002089853A2 Compositions having enhanced pharmacokinetic characteristics
11/14/2002WO2002089852A1 Soluble protein-polymer systems for drug delivery
11/14/2002WO2002089851A1 Method for making host-client complexes
11/14/2002WO2002089850A1 Long acting antimicrobic preparation
11/14/2002WO2002089849A1 Compositions and delivery systems for administration of a local anesthetic agent
11/14/2002WO2002089846A1 Topical medication for burns and wounds
11/14/2002WO2002089835A2 Pharmaceutical dosage form of amorphous nelfinavir mesylate
11/14/2002WO2002089821A1 Ophthalmic liquid preparation and liquid preparation for contact lens
11/14/2002WO2002089820A1 Formulation of amphiphilic heparin derivatives for enhancing mucosal absorption
11/14/2002WO2002089817A2 Anti-virus agent
11/14/2002WO2002089816A1 Method of administration of bisphosphonates by inhalation in the treatment or prevention of bone resorption and osteoporosis
11/14/2002WO2002089815A2 Disinfecting and solubilizing steroid compositions
11/14/2002WO2002089795A1 Method for treatment of tumors using nordihydroguaiaretic acid derivatives
11/14/2002WO2002089789A1 Trimethyl lock based tetrapartate prodrugs
11/14/2002WO2002089778A2 Transdermal therapeutic system for parkinson's disease inducing high plasma levels of rotigotine
11/14/2002WO2002089777A1 Improved transdermal therapeutic system for the treatment of parkinson's disese
11/14/2002WO2002089776A1 Nanoparticles made of protein with coupled apolipoprotein e for penetration of the blood-brain barrier and methods for the production thereof
11/14/2002WO2002089775A1 Coated granules based on angiotensin-converting enzyme inhibitor
11/14/2002WO2002089773A2 Pharmaceutical compositions comprising cyclosporin
11/14/2002WO2002089771A1 Liposomes
11/14/2002WO2002089768A1 Liquid injectable formulation of disodium pamidronate
11/14/2002WO2002089765A1 Method of preparing antibacterial gel and cotrimoxazole gel
11/14/2002WO2002089764A2 Gelatin substitute
11/14/2002WO2002089751A1 System and method for intranasal administration of lorazepam
11/14/2002WO2002089739A2 Peptide deformylase activated prodrugs
11/14/2002WO2002079393A9 Dynamic action reference tools
11/14/2002WO2002076476A3 Prodrugs of anticancer agents employing substituted aromatic acids
11/14/2002WO2002068562A9 Functionalized cubic liquid crystalline phase materials and methods for their preparation and use
11/14/2002WO2002067831B1 Composition for freshening nostrils and sinus cavities
11/14/2002WO2002064616A3 Agonists and antagonists of sphingosine-1-phosphate receptors
11/14/2002WO2002062392A3 Water-soluble compositions of bioactive lipophilic compounds
11/14/2002WO2002060339A3 Ophthalmic compositions for treating ocular hypertension
11/14/2002WO2002056918A3 Method of enhancing delivery of a therapeutic nucleic acid
11/14/2002WO2002045688A3 Composition for treatment of inflammatory disorders
11/14/2002WO2002044270A3 Use of comb copolymers based on acryloyldimethyltaurine acid in cosmetic, pharmaceutical and dermatological products
11/14/2002WO2001024839A9 Silver-containing compositions, devices and methods for making
11/14/2002WO2001024831A9 Polymer stabilized neuropeptides
11/14/2002WO2001007013A9 Thioamide moiety-containing polymer drug conjugates
11/14/2002US20020169332 Linoleic acid is converted to its conjugated forms in which the resulting composition is low in certain unusual isomers compared to conventional conjugated linoleic products
11/14/2002US20020169290 Nuclceotide sequences for use in the diagnosis, and prevent of multile sclerosis, viral infections, cancer, tumors, or tumour angiogenesis, and Chrohn's disease
11/14/2002US20020169264 Acylation with an acryloyl group of an amino group at some point in the peptide sequence, while still attached to the solid phase support with side chain groups intact, followed by deprotecting and free radical polymerization; vaccines
11/14/2002US20020169235 Which absorbs electromagnetic radiation, and uses the energy to trigger drug delivery; for multiples injections; diabetes
11/14/2002US20020169199 Ready-to-inject; buffer with pH of 7.2 to 4.0, a water-soluble organic solvent, an antioxidant and an agent which binds heavy metal ions
11/14/2002US20020169190 Dosing schedule of antitumor agents
11/14/2002US20020169144 Angiogenesis inhibition
11/14/2002US20020169142 Viscoelastics for use in middle ear surgery
11/14/2002US20020169135 Administration of a G1 and/or S phase drug, which is preferably beta-lapachone, or a derivative or analog thereof, combined with a G2/M phase drug such as a taxane derivative, which is advantageously paclitaxel
11/14/2002US20020169125 Fusion protein such as of polyglutamic acid and interferon-alpha; improves bioactivity and water-solubility properties of a drug to which it is conjugated
11/14/2002US20020169110 Diagnosis of metastatic cancer by the mts-1 gene
11/14/2002US20020168753 In vitro formation of congophilic maltese-cross amyloid plaques to identify anti-plaque therapeutics for the treatment of Alzheimer's and Prion diseases
11/14/2002US20020168662 Sperm protein 17 for the diagnosis and treatment of cancer
11/14/2002US20020168653 Nucleotide sequences coding polypeptide for use in the treatment of cell proliferative disorders
11/14/2002US20020168415 Biocompatible; culture product; anticancer agents
11/14/2002US20020168414 Rapid dehydration of proteins
11/14/2002US20020168413 Microstructure grains; fine particle size
11/14/2002US20020168412 Topical drug preparations
11/14/2002US20020168411 Spill resistant pharmaceutical system
11/14/2002US20020168409 Drug binded to polysaccharide, dextran; sustained release
11/14/2002US20020168407 Process for preparing low-viscosity, aqueous cellulose ether solutions
11/14/2002US20020168406 Gel overcoated with polylysine
11/14/2002US20020168404 Use of an acrylic type polymer as disintegrating agent
11/14/2002US20020168389 Oil in water emulsion; skin disorders
11/14/2002US20020168386 Instant granules and process for their formulation
11/14/2002US20020168381 Mixture of bone protein and ethylene oxide-propylene oxide copolymer; in situ administering
11/14/2002US20020168371 Process for reducing antibody response against xenografts
11/14/2002US20020168370 Methods and compositions for treating secondary tissue damage and other inflammatory conditions and disorders
11/14/2002US20020168366 Administering a binding agent capable of binding platelets binding platelets to the binding agent to form captured platelets, inducing activation of the captured platelets and forming a thrombus, which provides therapeutic benefit
11/14/2002US20020168355 Cationic liposome delivery of taxanes to angiogenic blood vessels
11/14/2002US20020168338 Compositions and methods for delivery of agents for neuronal regeneration and survival
11/14/2002US20020168336 Orthopedic implants or vehicles for sustained delivery of pharmaceutical, cosmetic and agricultural agents
11/14/2002US20020168334 Liquid formulations for the prevention and treatment of mucosal diseases and disorders
11/14/2002US20020168332 Composition comprising polymers having a star structure, the polymers, and their use
11/14/2002US20020168319 For providing local radiotherapy for therapy of tumor and arterio-venous malformations in a blood vessel
11/14/2002DE10122898A1 Use of 2-phenyl-4-chromanone derivatives to mask bitter or metallic tastes in foods, consumables and oral pharmaceutical products
11/14/2002DE10122855A1 Medicament composition containing oligoglycerol mono-ether derivative, as tissue membrane and organ barrier penetration improving agent to increase effectiveness of an active agent
11/14/2002DE10121982A1 Nanopartikel aus Protein mit gekoppeltem Apolipoprotein E zur Überwindung der Blut-Hirn-Schranke und Verfahren zu ihrer Herstellung Nanoparticles of protein with coupled apolipoprotein E to cross the blood-brain barrier and method for their preparation
11/14/2002CA2447470A1 Peptide deformylase activated prodrugs
11/14/2002CA2447045A1 Method for treatment of tumors using nordihydroguaiaretic acid derivatives
11/14/2002CA2446926A1 Dermatological formulations